bicalutamide has been researched along with epidermal growth factor in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartsch, G; Cronauer, MV; Culig, Z; Hittmair, A; Hobisch, A; Klocker, H; Radmayr, C; Trapman, J | 1 |
| Bartsch, G; Comuzzi, B; Culig, Z; Hobisch, A; Jasarevic, Z; Lodde, M; Nemes, C; Offner, F; Pycha, A; Schmidt, S | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Tombolini, V; Vicentini, C | 1 |
| Chuu, CP; Huo, C; Kao, YH | 1 |
5 other study(ies) available for bicalutamide and epidermal growth factor
| Article | Year |
|---|---|
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Topics: Androgen Antagonists; Anilides; Chloramphenicol O-Acetyltransferase; Epidermal Growth Factor; Fibroblast Growth Factor 10; Fibroblast Growth Factor 7; Fibroblast Growth Factors; Genes, Reporter; Growth Substances; Humans; Insulin-Like Growth Factor I; Male; Metribolone; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transfection; Tumor Cells, Cultured | 1994 |
The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Cell Line, Tumor; CREB-Binding Protein; Down-Regulation; Enzyme Inhibitors; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Interleukin-6; Male; Metribolone; Nitriles; Nuclear Proteins; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; RNA, Neoplasm; Tosyl Compounds; Trans-Activators; Tyrphostins; Up-Regulation | 2004 |
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Flow Cytometry; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Receptor, ErbB-2; Tosyl Compounds; Tumor Cells, Cultured | 2009 |
Androgen receptor inhibits epithelial-mesenchymal transition, migration, and invasion of PC-3 prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Humans; Insulin-Like Growth Factor I; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2015 |